Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
For the narrower MACE-3 composite of cardiovascular death, myocardial infarction, or stroke, 27 events occurred among participants receiving retatrutide compared with 23 in the placebo group, resulting in a hazard ratio of 1.12 (95% CI: 0.64-1.96)
Clinical manifestations may involve multiple systems, including neurological, gastrointestinal, and musculoskeletal domains
In contrast, Tirzepatide functions by a dual action, acting both as a GIP and GLP-1 receptor agonist
Qualified providers assess these factors during initial consultation to recommend personalized injection protocols that prioritize safety and comfort
US$ 22.87
US$ 29.67
US$ 25.89
US$ 27.93
US$ 21.97
